Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Noncardiac Surgery
Interventions: Fluid; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017 (peginterferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 12
States / cities: Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more

Conditions: Healthy Participants
Interventions: BMS-986308, Placebo (for BMS-986308), Furosemide; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Recalcitrant Wet Age-related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Northern California Retina Vitreous Associates; Other
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Drug Toxicity Psychotropic Agents Psychostimulants
Interventions: Ryanodex (dantrolene sodium) for injectable suspension; Drug
Lead sponsor: Eagle Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Electronic Cigarette Use
Interventions: Subox Mini C with Avail 18 mg nicotine salt (protonated), Subox Mini C with Avail 18 mg nicotine (unprotonated), Own brand cigarette; Other
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 21 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Meningoencephalitis, Other Syndromes Requiring Lumbar Puncture in Emergency Department
Interventions: no intervention; Other
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 3 Months and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Sylmar, California

Conditions: Hypothermia
Interventions: Air-Activated heating packs, Forced Air Warming Device; Device
Lead sponsor: Dr K Services PC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: Stress, Fatigue
Interventions: Blue Burn Tincture; Dietary Supplement
Lead sponsor: Apothekary; Industry
Eligibility: 30 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Vegetables, Cardiovascular Disease, Blood Pressure
Interventions: Vegetable Juice; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Davis, California

Conditions: Fasciitis, Plantar
Interventions: ReNu Injection, Corticosteroid Injection; Other
Lead sponsor: NuTech Medical, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Denver, Colorado • Orlando, Florida • West Des Moines, Iowa + 3 more

Conditions: Bypass, Gastric, Roux-en-Y Gastric Bypass, Vertical Sleeve Gastrectomy, Gastric Banding, Bariatric Surgery
Interventions: Placebo, Lo-Xenin, Hi-Xenin, Extra Hi-Xenin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cardiovascular Risk Factors
Interventions: Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE); Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 213
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Keratoconjunctivitis Sicca, Dry Eye Syndromes, Ocular Surface Disease, Sjogren's Syndrome
Interventions: Questionnaires, Tear fluid sampling, Impression Cytology; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cervical Disease
Interventions: CNDS Advanced Cervical Scan; Device
Lead sponsor: Guided Therapeutics; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
Interventions: SV2A PET, TSPO PET; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay, western blotting, electron microscopy, high performance liquid chromatography, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, pharmacological study; Drug · Genetic · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neuroblastoma, Cancer
Interventions: Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib; Procedure · Genetic · Other + 2 more
Lead sponsor: Yael P Mosse; Other
Eligibility: 1 Year to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson Disease
Interventions: Standard of care + Mediterranean diet (intervention), Standard of care (control); Other
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 85 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acute Kidney Injury, Fluid Overload, Hypotension, Dialysis; Complications, Critical Illness
Interventions: Restrictive UFnet Rate Strategy, Liberal UFnet Rate Strategy; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more

Conditions: Pain Management, Postoperative Pain
Interventions: PCDD Generation 1 system; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

ZYNEX Cardiac Monitor in Patients Having Noncardiac Surgery

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

Effects of Nicotine Salt Aerosol on Cigarette Smokers

Prevalence of Pathogens in Cerebrospinal Fluid Obtained From Emergency Department Patients

Efficacy of Warming Garment in the Perioperative Period With Integrated Chemical Heat Packs to Maintain Normothermia

A Clinical Trial to Evaluate the Effects of a Herbal Tincture on Energy Levels, Weight Management, and Markers of Metabolic Health

Clinical Investigation on the Effects of a Vegetable Juice Treatment

ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis

To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery

Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye

Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

Next Generation Personalized Neuroblastoma Therapy

Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease a Randomized, Controlled, Clinical Trial

Restrictive Versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

PCDD Generation 1 Oral Liquid Acetaminophen Delivery Evaluation